Last updated: February 13, 2026
Overview
NDC 00093-3219 is a pharmaceutical product manufactured by Johnson & Johnson, identified as Remicade (infliximab). It is an injectable monoclonal antibody used primarily for autoimmune diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Approved by the FDA since 1998, Remicade has experienced consistent growth aligned with its patent exclusivity and subsequent biosimilar entries.
Market Size and Growth Dynamics
Historical Market Trends
The global infliximab market was valued at approximately USD 9.5 billion in 2021 and is projected to reach USD 11.8 billion by 2027, growing at a CAGR of around 4.2% (CAGR specific to infliximab). The North American market dominates, accounting for approximately 45% of global sales, driven by high prevalence of autoimmune diseases and strong healthcare infrastructure.
Key Drivers
- Increasing prevalence of autoimmune diseases.
- Expanding indications for infliximab.
- Rising adoption of biologics over traditional immunosuppressants.
- Patent expirations and entry of biosimilars.
Competitive Landscape
Primary competitors include:
- Biosimilars: Inflectra (Pfizer), Renflexis (Samsung Bioepis), Ixifi (Samsung Bioepis), and others.
- Originator molecule: Remicade until patent expiry in 2018.
Post-expiry, biosimilar penetration has increased. In the U.S., biosimilar market share reached roughly 60% of infliximab prescriptions by 2022, with prices declining significantly.
Pricing History and Projections
Current Price (2023)
- Brand (Remicade): Approximate wholesale acquisition cost (WAC) is USD 3,300 to USD 3,600 per vial (100 mg).
- Biosimilars: Priced roughly 30-50% below the brand, around USD 1,800 to USD 2,500 per vial.
Price Trends Post-Biosimilar Entry
- The original infliximab price declined by 20-25% within two years of biosimilar launch in the U.S.
- Biosimilar prices have stabilized at 35-45% discounts compared to the originator.
Future Price Projections (Next 3-5 Years)
| Scenario |
Wholesale Price per 100 mg Vial |
Assumptions |
| Conservative Decline |
USD 2,500 |
Market saturation, slow biosimilar adoption |
| Moderate Decline |
USD 2,000 |
Increased biosimilar penetration, competition |
| Aggressive Decline |
USD 1,700 |
Patent cliff effects, aggressive biosimilar uptake |
Note: These are wholesale list prices; actual transaction prices vary based on payer negotiations, rebates, and procurement contracts.
Regulatory and Policy Impact
- Biosimilar approval pathways by the FDA (Addition of multiple biosimilars since 2016) have driven prices down.
- US Medicaid and commercial insurers increasingly favor biosimilars, pressuring originator prices.
- International markets exhibit variable biosimilar adoption, influencing global pricing.
Market Entry and Off-Label Use
- New indications: Extended labeling for additional autoimmune conditions can expand market size.
- Off-label use remains a concern; however, patent considerations and biosimilar competition limit pricing power.
Price and Revenue Impact of Biosimilar Competition
| Year |
Infliximab Market Share (biosimilars) |
Originator Market Share |
Approximate Revenue (USD billion) |
| 2022 |
60% |
40% |
USD 4.5 (originator) |
| 2023 |
70% |
30% |
USD 3.36 |
| 2025 |
80% |
20% |
USD 2.4 |
Price erosion continues as biosimilars capture market share.
Key Takeaways
- NDC 00093-3219 (Remicade) remains a significant player in autoimmune disease therapeutics.
- Biosimilar competition has dramatically reduced prices, with a potential further decline of 15-20% over the next 2-3 years.
- Market growth will depend on expansion into new indications and geographic regions.
- The US market faces ongoing pricing pressures; global markets vary by regulatory environment and biosimilar uptake.
- Overall revenue for the infliximab segment in 2023 is approximately USD 4.5 billion, declining gradually as biosimilar penetration increases.
FAQs
1. How will biosimilar entry affect the market for NDC 00093-3219?
Biosimilars have reduced the price of infliximab by 30-50%, capturing significant market share. This trend is expected to continue, likely reducing the originator’s revenue by 20-30% annually over the next 2-3 years.
2. What are the main factors driving price decline?
Market saturation with biosimilars, increased payer negotiations, and policy incentives favoring biosimilars contribute to price reductions.
3. Are there upcoming regulatory changes that could influence pricing?
Potentially, new biosimilar approvals and patent litigations can impact pricing. The FDA continues to facilitate biosimilar approval, incentivizing competition.
4. How does international market variability impact overall pricing?
Countries with regulatory barriers or lower biosimilar adoption rates retain higher prices. Emerging markets may see slower price declines due to weaker biosimilar infrastructure.
5. What is the outlook for new indications for infliximab?
Expanded approvals could expand the market, supporting stable or slightly increased prices, offsetting biosimilar price pressures.
Citations
- Grand View Research. "Infliximab Market Size, Share & Trends Analysis Report," 2022.
- IQVIA. "US Biosimilar Market Data," 2022.
- FDA. "Biosimilar Approval Pathway," 2016.
- Evaluate Pharma. "Biologic Market Forecast," 2023.
- Centers for Medicare & Medicaid Services. "Biosimilar Policy Updates," 2023.
